Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BIO maps incentives for neglected diseases

Executive Summary

The Biotechnology Industry Organization highlights incentives for innovation for diseases in developing countries, including Advanced Market Commitments, R&D tax incentives, priority review vouchers, transferable exclusivity, Track II patents and even prizes in the paper released June 18 at the BIO International Convention in San Diego, Calif. Some of the incentives are already being adopted. For example, the FDA Amendments Act includes a mechanism to encourage development of tropical diseases - including AIDS - by offering sponsors a transferable priority review voucher. Additionally, an investigational version of Wyeth's currently marketed Prevnar is an anticipated candidate for a pediatric pneumococcal AMC, as is an investigational vaccine, Streptorix, being developed by GlaxoSmithKline (1"The Pink Sheet," Nov. 26, 2007, p. 24)
Advertisement

Related Content

Wyeth, GSK Vaccines May Get Sales Boost Under Pilot For Developing Countries
Wyeth, GSK Vaccines May Get Sales Boost Under Pilot For Developing Countries
Advertisement
UsernamePublicRestriction

Register

PS049774

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel